Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-7 DC Vaccine in Gastric Cancer
NCT04567069Phase 2Unknown
- Sponsor
- Second Hospital of Shandong University
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of MG-7 antigen-pulsed autologous dendritic cell vaccine in gastric cancer (GC) (3 arms), sponsored by Second Hospital of Shandong University. Primary endpoints: Objective Response Rate at 6 months, Disease Control Rate at 6 months and 2 more. Status: unknown.
02
Drugs
MG-7 antigen-pulsed autologous dendritic cell vaccine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04567069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567069.